CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.
Domenig SA, Bundschuh N, Lenardic A, Ghosh A, Kim I, Qabrati X, D'Hulst G, Bar-Nur O
Stem Cell Reports. 2022 Feb 8;17(2):321-336. doi: 10.1016/j.stemcr.2021.12.003. Epub 2022 Jan 6. PubMed Article
Domenig SA, Bundschuh N, Lenardic A, Ghosh A, Kim I, Qabrati X, D'Hulst G, Bar-Nur O
Stem Cell Reports. 2022 Feb 8;17(2):321-336. doi: 10.1016/j.stemcr.2021.12.003. Epub 2022 Jan 6. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 184379 | pLV[Exp]-Neo-EF1A>Tet3G | The Tet3G gene is expressed under a constitutive EF1-alpha promoter. This protein binds a TRE3G promoter to activate gene transcription only in the presence of tetracycline or its analogs (e.g. doxycycline) |
| 184380 | pLV[Tet]-Puro-TRE3G>mMyod1[NM_010866.2] | The mouse Myod1 gene is expressed under a doxcycline-inducible TRE3G promoter |
| 184381 | pRP[2CRISPR]-mCherry/Hygro-hCas9-U6>{mdx left}-U6>{mdx right} | This plasmid contains hCas9 and two gRNAs that can excise the genomic area around the mouse mdx mutation in dystrophin's exon 23 |